Mercedes Meyer, Ph.D., represents leading life science and technology companies and maintains an extensive biotechnology and pharmaceutical patent management, prosecution, opinion, and due diligence practice. With a doctorate in virology and a degree in chemistry, Meyer has a deep understanding of complex biotechnology and scientific research, which is key for advising life science clients on commercializing and protecting product innovations as well as performing diligence for investing in new technologies, particularly in corporate joint development projects. Meyer advises on developing patent strategies, managing intellectual property rights, and making associated investments and acquisitions. Meyer also handles patent reexaminations and inter partes matters.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Global IP Lawyers | 2026 | Patent, Portfolio, Prosecution |
| The Inaugural Lawdragon 500 Leading Global IP Lawyers | 2025 | Patent, Portfolio, Prosecution |
In 2023, Meyer was awarded the Intellectual Property Owner Association Carl B. Horton Distinguished Service Award, recognizing her as an individual who displays extraordinary leadership and dedication to promoting the value of intellectual property. Most recently, she received the 2025 Inspiring Woman of the Year Award at the Life Sciences Patent Network (LSPN) Awards. She is a Fellow and former Board member of the American Intellectual Property Law Association and currently serves on the Board of Directors for the Intellectual Property Owners Education Foundation (IPOEF). . She currently serves as a Vice Chair of the IPO’s Pharmaceutical & Biotechnology Issues Committee.
Meyer is passionate about helping the legal community find solutions to enhance lawyer mental health, increase diversity, reduce substance abuse, and promote neurodiversity in productive teams, and frequently speaks to organizations and corporate leaders on these topics. In 2025, Meyer received the ACC Chapter Achievement Award for Most Innovative Programming Effort, alongside fellow panelists, for their neurodiversity and ethics presentation.
Meyer is a tireless thought leader in the life science community co-authoring the following articles: Killing the Golden Goose of U.S. Drug Innovation: Follow the Money for Life Sciences Intellectual Property Review and Regulation and Ethics in AI-Supported Health Care for Juriste International